Annual CFF
$11.86 M
-$41.80 M-77.90%
December 31, 2023
Summary
- As of February 20, 2025, CUE annual cash flow from financing activities is $11.86 million, with the most recent change of -$41.80 million (-77.90%) on December 31, 2023.
- During the last 3 years, CUE annual CFF has fallen by -$46.75 million (-79.77%).
- CUE annual CFF is now -80.87% below its all-time high of $62.00 million, reached on December 31, 2017.
Performance
CUE Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$9.82 M
+$10.82 M+1082.10%
September 30, 2024
Summary
- As of February 20, 2025, CUE quarterly cash flow from financing activities is $9.82 million, with the most recent change of +$10.82 million (+1082.10%) on September 30, 2024.
- Over the past year, CUE quarterly CFF has increased by +$10.82 million (+1082.10%).
- CUE quarterly CFF is now -84.17% below its all-time high of $62.05 million, reached on December 31, 2017.
Performance
CUE Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$15.96 M
+$5.23 M+48.78%
September 30, 2024
Summary
- As of February 20, 2025, CUE TTM cash flow from financing activities is $15.96 million, with the most recent change of +$5.23 million (+48.78%) on September 30, 2024.
- Over the past year, CUE TTM CFF has increased by +$5.23 million (+48.78%).
- CUE TTM CFF is now -82.82% below its all-time high of $92.86 million, reached on September 30, 2020.
Performance
CUE TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
CUE Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -77.9% | +1082.1% | +48.8% |
| 3 y3 years | -79.8% | -64.2% | -70.3% |
| 5 y5 years | +183.6% | -64.2% | -70.3% |
CUE Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -77.9% | at low | -64.2% | +1082.1% | -70.3% | +48.8% |
| 5 y | 5-year | -79.8% | at low | -77.3% | +1082.1% | -82.8% | +48.8% |
| alltime | all time | -80.9% | +183.6% | -84.2% | +1082.1% | -82.8% | >+9999.0% |
Cue Biopharma Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $9.82 M(-1082.1%) | $15.96 M(+48.8%) |
| Jun 2024 | - | -$1.00 M(-142.5%) | $10.72 M(-22.4%) |
| Mar 2024 | - | $2.35 M(-50.8%) | $13.83 M(+16.6%) |
| Dec 2023 | $11.86 M(-77.9%) | $4.78 M(+4.2%) | $11.86 M(-65.6%) |
| Sep 2023 | - | $4.59 M(+118.4%) | $34.48 M(+15.4%) |
| Jun 2023 | - | $2.10 M(+441.5%) | $29.88 M(-23.2%) |
| Mar 2023 | - | $388.00 K(-98.6%) | $38.89 M(-27.5%) |
| Dec 2022 | $53.66 M(+179.0%) | $27.40 M(<-9900.0%) | $53.66 M(+59.5%) |
| Sep 2022 | - | -$9000.00(-100.1%) | $33.64 M(-1.1%) |
| Jun 2022 | - | $11.11 M(-26.7%) | $34.00 M(+1.3%) |
| Mar 2022 | - | $15.16 M(+105.3%) | $33.56 M(+74.5%) |
| Dec 2021 | $19.23 M(-67.2%) | $7.38 M(+2003.2%) | $19.23 M(+59.0%) |
| Sep 2021 | - | $351.00 K(-96.7%) | $12.10 M(-54.8%) |
| Jun 2021 | - | $10.67 M(+1178.9%) | $26.76 M(-55.0%) |
| Mar 2021 | - | $834.00 K(+241.4%) | $59.41 M(+1.4%) |
| Dec 2020 | $58.61 M | $244.30 K(-98.4%) | $58.61 M(-36.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2020 | - | $15.01 M(-65.3%) | $92.86 M(+3.0%) |
| Jun 2020 | - | $43.32 M(>+9900.0%) | $90.14 M(+78.3%) |
| Mar 2020 | - | $36.00 K(-99.9%) | $50.57 M(-0.4%) |
| Dec 2019 | $50.79 M(+1114.5%) | $34.49 M(+180.6%) | $50.79 M(+148.2%) |
| Sep 2019 | - | $12.29 M(+228.0%) | $20.47 M(+150.0%) |
| Jun 2019 | - | $3.75 M(+1358.0%) | $8.19 M(+84.4%) |
| Mar 2019 | - | $257.00 K(-93.8%) | $4.44 M(+6.1%) |
| Dec 2018 | $4.18 M(-93.3%) | $4.17 M(>+9900.0%) | $4.18 M(-93.3%) |
| Sep 2018 | - | $12.00 K(>+9900.0%) | $62.06 M(+0.1%) |
| Jun 2018 | - | $0.00(0.0%) | $62.03 M(+0.0%) |
| Mar 2018 | - | $0.00(-100.0%) | $62.00 M(0.0%) |
| Dec 2017 | $62.00 M(+313.2%) | $62.05 M(<-9900.0%) | $62.00 M(<-9900.0%) |
| Sep 2017 | - | -$22.00 K(0.0%) | -$44.00 K(+100.0%) |
| Jun 2017 | - | -$22.00 K | -$22.00 K |
| Dec 2016 | $15.01 M(+69.2%) | - | - |
| Dec 2015 | $8.87 M | - | - |
FAQ
- What is Cue Biopharma annual cash flow from financing activities?
- What is the all time high annual CFF for Cue Biopharma?
- What is Cue Biopharma annual CFF year-on-year change?
- What is Cue Biopharma quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Cue Biopharma?
- What is Cue Biopharma quarterly CFF year-on-year change?
- What is Cue Biopharma TTM cash flow from financing activities?
- What is the all time high TTM CFF for Cue Biopharma?
- What is Cue Biopharma TTM CFF year-on-year change?
What is Cue Biopharma annual cash flow from financing activities?
The current annual CFF of CUE is $11.86 M
What is the all time high annual CFF for Cue Biopharma?
Cue Biopharma all-time high annual cash flow from financing activities is $62.00 M
What is Cue Biopharma annual CFF year-on-year change?
Over the past year, CUE annual cash flow from financing activities has changed by -$41.80 M (-77.90%)
What is Cue Biopharma quarterly cash flow from financing activities?
The current quarterly CFF of CUE is $9.82 M
What is the all time high quarterly CFF for Cue Biopharma?
Cue Biopharma all-time high quarterly cash flow from financing activities is $62.05 M
What is Cue Biopharma quarterly CFF year-on-year change?
Over the past year, CUE quarterly cash flow from financing activities has changed by +$10.82 M (+1082.10%)
What is Cue Biopharma TTM cash flow from financing activities?
The current TTM CFF of CUE is $15.96 M
What is the all time high TTM CFF for Cue Biopharma?
Cue Biopharma all-time high TTM cash flow from financing activities is $92.86 M
What is Cue Biopharma TTM CFF year-on-year change?
Over the past year, CUE TTM cash flow from financing activities has changed by +$5.23 M (+48.78%)